Nephrogenic systemic fibrosis is a medical disorder which is extremely rare and which occurs among individuals who undergo exposure to an intravenous contrast material that contains gadolinium or in individuals that have reduced kidney function. Nephrogenic Systemic Fibrosis (NSF) Treatment involves treating the hardened or thickened fibrosis of the subcutaneous tissues, skin, or, at times, underlying skeletal muscles. Nephrogenic Systemic Fibrosis (NSF) Treatment is usually performed for legs and arms.
This report contains market size and forecasts of Nephrogenic Systemic Fibrosis (NSF) Treatment in Global, including the following market information:
Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Nephrogenic Systemic Fibrosis (NSF) Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Hemorrheologic Agents Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Nephrogenic Systemic Fibrosis (NSF) Treatment include Pfizer, Sanofi, Allergan, Novartis, Johnson & Johnson, Bausch Health, Merck and Teva Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Nephrogenic Systemic Fibrosis (NSF) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Segment Percentages, by Type, 2021 (%)
Hemorrheologic Agents
Immunomodulatory Drug
Alkylating Agents
Kinase Inhibitors
Others
Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Nephrogenic Systemic Fibrosis (NSF) Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Nephrogenic Systemic Fibrosis (NSF) Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Nephrogenic Systemic Fibrosis (NSF) Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Sanofi
Allergan
Novartis
Johnson & Johnson
Bausch Health
Merck
Teva Pharmaceuticals